Background: How breast cancers respond to endocrine therapy strongly depends on the
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Background
Estrogen and progesterone are main players in the normal development and function of the mammary gland as well as in the progression and outcome of breast cancers [1] . Both hormones act through their cognate receptors (estrogen receptor, ER, and progesterone receptor, PR), which function as signaling triggers and as ligand-activated transcription factors [1] . Of the approximately two-thirds of breast cancers that express the ER protein, about half also express the PR protein and are therefore classified as ER+/PR+ [2] . ER+/PR+ tumors tend to be highly differentiated and responsive to hormone therapies, in contrast to ER-positive tumors lacking PR, which are less likely to respond to endocrine therapy [2] .
Approximately one-third of breast cancers lack both ER and PR (ER-/PR-) and generally shows poor histological differentiation with higher growth rates [2] . These cancers rarely respond to hormone therapies and exhibit a poor clinical outcome compared to ER+/PR+ breast cancers [2] . Hence, understanding the molecular mechanism that controls the expression of these hormone receptors in tumor cells is an important area of investigation.
Genetic mutations of the ERα coding gene (ESR1), such as deletions, rearrangements, and point mutations, are not frequent enough to explain the loss of ESR1 expression in up to onethird of human breast cancers [2] . In contrast, a gain of methylation of the CpG island localized at the ESR1 promoter frequently occurs and results in reduced or no ERα expression [3] [4] . CpG islands are cytosine/guanosine-rich genomic sequences located in the regulatory regions of genes. They are generally unmethylated in normal somatic cells, with the 4 exception of imprinted genes [5] . In cancer cells, however, a gain of CpG island methylation is associated with transcriptional silencing, either directly or through a change in chromatin conformation [5] . Initially, it was reported that there was no correlation between loss of ESR1 expression and methylation of the coding region of ESR1 in breast cancer [6] . However, a clear correlation between the lack of ESR1 expression and gene promoter methylation has been shown [3] [4] . Moreover, breast cancer patients with poor prognosis tend to have higher DNA methylation levels at the ESR1 promoter [7] . The analysis of ESR1 promoter methylation status, therefore, can be critical for stratifying breast cancers.
Upon hormone exposure, PR and ER mediate breast cancer cell response and strongly affect cell growth, migration and invasion [1] . Both hormone-activated receptors exhibit enhanced binding to specific DNA sequences called hormone-responsive elements, which are generally located within target gene enhancers or promoters [1, 8] . The DNA-bound receptors orchestrate the assembly of large cofactor-containing protein complexes that can either positively or negatively affect gene transcription [1] . In addition, hormone-activated ER and PR attached to the cell membrane can trigger rapid signaling by interacting with several kinases, which also participate in hormonal gene regulation [1, 9] .
In the absence of hormones, unliganded PR and ER also profoundly affect the breast cancer cell biology. Unliganded ER inhibits breast cancer cell growth and is required for the maintenance of the cell epithelial phenotype [10, 11] . The silencing of ER in breast cancer cells, indeed, induces epithelial to mesenchymal transition [11] . Moreover, the presence of this protein plays a key role in the breast cancer sensitivity to the endocrine therapy [12] . 5 Interestingly, as the unliganded ER, also the unliganded PR enhances breast cancer response to estrogen and to selective ER modulator used for the endocrine therapy, including tamoxifen and others antiestrogens [12] [13] [14] . However, how the presence of PR affects the breast cancer sensitivity to these external stimuli is not completely understood. Thus, the study of the role of unliganded hormone receptors in breast cancer cells helps to understand how epithelial breast cancer cells maintain cell homeostasis and how they respond to external stimuli including the ER modulators used for the endocrine therapy.
About one-third of breast cancers are resistant to steroid hormones but often retain functional hormone receptors [15] and remain highly sensitive to growth factors including EGFR (epidermal growth factor receptor) [16] . Growth factors stimulate breast cancer cell proliferation by enhancing the transcriptional activity of unliganded PR via the protein kinases signaling pathways [16] . The activated unliganded PR directly regulates gene expression by acting at chromatin level [17] , even if the molecular mechanisms put into play are poorly understood. In hormone-free breast cancer cells, phosphorylated and undersumoylated PR positively regulates the expression of growth promoting genes by recruiting steroid receptor coactivator 1 (SRC1) to gene promoters [17] . In contrast, sumoylated PR down-regulated the expression of the same class of genes by recruiting histone deacetylase 3 (HDAC3) to promoters [17] . On the other hand, unliganded ERα directly regulates the expression of hundred genes including the PR-encoding gene (PGR) in hormone-deprived breast cancer cells by modulating the extent of trimethylation of lysine 27 on histone 3 (H3K27me3) at ERα binding sites [18] . 6 The key role of unliganded PR for the responsiveness of breast cancers to growth factors and endocrine therapy as well as the high correlation between the PR and ER levels in breast cancers [19] led us to explore whether and how unliganded PR regulates the ESR1 expression in hormone-free breast cancer cells. Here we report that unliganded PR binds to the lowmethylated ESR1 promoter to maintain its basal expression and its low level of DNA methylation in hormone-deprived breast cancer cells. Consistent with these data, we show that DNA methylation hinders PR binding to hormone-responsive elements.
Methods
Cell culture
The T47D-MTVL (T47D) breast cancer cells used in this study have a stably integrated copy of the luciferase reporter gene driven by the MMTV promoter [20] . The T47D, T47D-Y [21] , T47D-Y+PR [21] , MCF7 and BT474 cells were routinely grown in medium (RPMI 1640 for T47D; DMEM for all the other cell lines) supplemented with 10% FBS and standard antibiotics. For the experiments, cells were grown 48 hours in medium without phenol red supplemented with 10% dextran-coated charcoal treated FBS (DCC/FBS). In contrast to normal FBS, the DCC/FBS does not contain hormone-similar compounds that can activate the PR activity. Moreover, since the cell cycle phase can influence the PR activity [22] , cells were synchronized in G0/G1 by serum starvation for 16 hours to avoid the cell cycle phase variability. For 5-azacytidine treatment, T47D-Y+PR cells were grown for 96 hours (48 hours using DMEM medium supplemented with 10% FBS, and 48 hours with DMEM without phenol red supplemented with 10% DCC/FBS) with 5 µM of 5-azacytidine (A3656, 7 Sigma-Aldrich) or vehicle (1:1 acetic acid to water). Cells were finally synchronized in G0/G1 by 16 hours of serum starvation before performing chromatin immunoprecipitation assay.
Lentivirus preparation and infection
HEK-293 cells were transfected with pVSV-G [23] and pCMV∆R8.91 [24] , together with the pLKO.1-puro non-targeting vector (SHC001; Sigma-Aldrich) or pLKO.1-shRNA against PR using CaCl2 to permeabilize the cell membrane. Two different clones of PLKO.1-shRNA against PR have been used: clone trcn0000010776 and clone trcn0000003321 (SHCLND-NM_000926, Sigma-Aldrich). The viral particles containing the shRNA were collected 72 hours after the transfection and used to stably infect breast cancer cells. Cell populations were finally selected with puromycin (1 g/ml) and processed to quantify mRNA and protein expression.
Reverse transcription and quantitative PCR
Total RNA was isolated with the RNeasy extraction kit (Qiagen). Complementary DNA (cDNA) was generated from 100ng of total RNA with the First Strand cDNA Superscript II Synthesis kit (Invitrogen; #11904018) and analyzed by quantitative PCR. Gene-specific expression was regularly normalized to GAPDH expression. Primers sequences are listed in table S1. 8 Cell lysates were resolved on SDS-polyacrylamide gels, and the proteins were transferred to Hybond-ECL nitrocellulose membranes (Amersham). Membranes were blocked with TBS-0.1% Tween 20 (TBS-T) with 5% of skimmed milk, incubated for 1 hour at room temperature with a primary antibody (antibody against PR, sc-7208 from Santa Cruz Biotechnology; antibody against ERα, sc-543 from Santa Cruz Biotechnology; antibody against -tubuline, T9026 from Sigma), and then diluted in TBS-T with 2.5% skimmed milk. After three washes with TBS-T, membranes were incubated for 45 min at room temperature with horseradish peroxidase-conjugated secondary antibodies (GE Healthcare). Antibody binding was detected by chemiluminescence on a LAS-3000 image analyzer (Fuji PhotoFilm).
Western blotting
Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) assays were performed as described previously [25] , with minor modifications. Cells were cross-linked in medium containing 1% formaldehyde for 10 min at 37°C, and crosslinking was quenched with 125 mM glycine for 5 min at room temperature. After cells were lysed in hypotonic buffer, the nuclei were lysed with SDS-lysis buffer. Chromatin was sheared by sonication and incubated 16 hours with 5μg of antibody against progesterone receptor (PR, Santa Cruz Biotechnology, sc-7208) or rabbit IgG (Cell Signaling, #2729s). Immunocomplexes were recovered with protein A agarose bead slurry (Diagenode, #C03020002) for 2 hours with rotation and washed with ChIP buffer (Diagenode, #K0249001) and Tris-EDTA buffer. For reversing the crosslinking, samples were incubated with proteinase K (10 mg/ml) at 65ºC for 16 hours. DNA was purified and analyzed by quantitative PCR. Primer sequences are listed in table S1. 
ChIP-sequencing analysis
For PR ChIP-seq, the reads of the previously published PR ChIP-seq [20] were trimmed using Trimmomatic (version 0.33) with the parameters values recommended by Bolger et al. [26] . The trimmed reads were aligned to the hg19 assembly version of the human genome using BWA (version: 0.7.12-r1039) [27] . The FASTA file containing the genome reference sequence of hg19 was downloaded from the UCSC Genome Browser discarding the random scaffolds and the alternative haplotypes from the reference sequence for the alignment [28] .
BWA-MEM algorithm and SAMtools (version: 1.2, using htslib 1.2.1) [29] were used to convert SAM files to BAM files and to sort them to retain only uniquely aligned reads. The PR binding sites were identified with the MACS2 tool (version 2.1.0.20150420) [30] . Peaks were additionally filtered until those remaining had a false discovery rate (FDR) qvalue < 10 -6 and a 4-fold enrichment over the control sample (input), leaving 476 peaks for subsequent analyses.
DNA methylation
The DNA methylation analyses were performed by methylated DNA immunoprecipitation assay coupled with quantitative-PCR (MeDIP-qPCR) or high-throughput sequencing (MeDIP-seq). For MeDIP-qPCR, genomic DNA was randomly sheared by sonication to generate fragments between 300 and 700 bp. Sonicated DNA was denatured and then immunoprecipitated as previously described [31] using an antibody against 5mC using the reference human genome version 19 (hg19) [32] . The mapped reads were filtered for duplicates and used to compute genome-wide reads-per-million (RPM) normalized signal tracks. The 5mC and CpG heat maps were generated using DeepTools (version 2.2.0) [33] and BEDtools (version v2.24.0) [34] and the matrix underlying the heatmaps was used to generate the 5mC and CpG average profiles. To test the significance of the overall reduction of 5mC methylation observed in the progesterone-receptor binding sites (PRBs), we calculated the average 5mC normalized read counts signal over each PRBs and random regions resulting from shuffling the genomic coordinates of the PRBs, while keeping their sizes as in the true set of regions (this second step was repeated 1,000 times to generate an empirical null distribution of 5mC methylation averaged values). The Mann-Whitney U Test was applied using the stats module of the Python's SciPy library [35] .
Electrophoresis mobility-shift assay
Recombinant human PR (isoform B; PRB) was expressed in baculovirus and purified as previously described [36] . Radioactive double-stranded oligonucleotides containing the 
Results
PR is required to maintain ESR1 gene basal expression in hormone-deprived breast cancer cells
Comparing the ESR1 gene expression in T47D breast cancer cells and a derived clone selected for low PR expression (T47D-Y) [21] , as previously observed [37] , we confirmed that low PR expression is accompanied by a low expression of ESR1 at both the transcript and protein levels (Fig. 1, A 
PR binds to the ESR1 locus in hormone-deprived breast cancer cells
To test whether PR directly regulates ESR1 gene expression prior to hormone stimulation, we analyzed ChIP-seq data obtained with an antibody to PR in serum-starved T47D cells [20] . In the absence of hormones, PR appears to bind to two genomic regions within the ESR1 locus, one located within the gene promoter (chromosome 6: 152,128,500-152,129,000 hg19) and another within the third intron (chromosome 6: 152,222,250-152,222,650 hg19) (Fig 2A) . The specificity of these two unliganded PR binding events was confirmed by ChIPqPCR using T47D cells and PR-deficient cells (T47D-Y) or PR-depleted cells (shPR). PR 13 bound to the promoter and the intronic regions in T47D cells but not in T47D-Y cells ( Fig   2B, left panel) or in shPR cells (Fig 2B, right panel) . Strikingly, our analysis of previously published ChIP-seq experiments performed in the same conditions [8, 39] revealed that the intronic sequence bound by PR in hormone-deprived T47D cells exhibited marks of active enhancers, including histone H3 mono-methylation on lysine 4 (H3K4me1) and DNase hypersensitivity (Fig 2A) [40] .
We also tested PR binding at ESR1 locus in MCF7 cells by ChIP-qPCR and found that in this case unliganded PR also bound at ESR1 promoter but not at the enhancer-like site in the third intron of ESR1 gene (Fig S2) .
Rescue of PR does not restore ESR1 gene expression in PR-deficient cells
To explore whether stable expression of PR restores ESR1 gene expression, we stably expressed PR in PR-deficient cells (T47D-Y+PR) and analyzed ESR1 expression.
Unexpectedly, ESR1 expression remained significantly reduced at both transcript and protein levels after re-establishing PR levels (Fig 3, A and B) . Similarly, the estrogen-mediated induction of the TFF1 gene remained reduced after PR rescue (Fig 3C) . Thus, PR expression alone is insufficient to restore ESR1 gene expression to a level comparable to wild-type cells, suggesting that the ESR1 gene is stably repressed through another mechanism once PR is absent in T47D breast cancer cells.
Lack of PR affects DNA methylation at the ESR1 promoter
DNA methylation at the ESR1 promoter represents one of the main epigenetic mechanisms for stably repressing ESR1 expression in breast cancers [4, 7] . To explore whether PR loss 14 affects the DNA methylation profile of the ESR1 locus, we compared the DNA methylation pattern at the ESR1 promoter and intronic PR-binding sites between T47D control cells, PR deficient cells (T47D-Y) (Fig 4A) , and PR-depleted cells (shPR) (Fig 4B) before and after PR rescue. Methylation of the ESR1 promoter was strongly increased in PR-deficient and PR-depleted cells, and high DNA methylation amount of this genomic region persisted after PR rescue (T47D-Y+PR cells) (Fig 4A) . In contrast, the DNA methylation profile of the intronic-PR binding site was not increased, neither in PR deficient nor PR depleted cells, and did not significantly change after PR rescue (Fig 4A) .
Consistent with these data, we observed that analysis of the TGCA Breast Invasive carcinoma (BRCA) dataset showed a clear difference in ESR1 gene methylation levels when the data was segregated based on the PR expression levels of the patients. PR negative breast carcinoma patients were more commonly also negative for ER and present an increased level of methylation of the ESR1 gene than PR-positive breast carcinomas. The gain of ESR1 methylation in PR-negative breast carcinomas was stronger at gene promoter rather than within gene body (Fig S3) .
DNA methylation impedes PR binding to hormone responsive elements
DNA methylation can directly affect the affinity of transcription factors towards their binding sites [41] . To check whether higher ESR1 promoter methylation levels affect PR binding to this genomic region, we compared PR binding levels at the ESR1 locus between T47D control cells, PR-deficient cells (T47D-Y), and PR-rescue cells (T47D-Y+PR) by ChIP-qPCR assay.
As described above, PR bound to the ESR1 promoter and to an enhancer-like intronic sequence in control cells, whereas, this binding was completely impaired in PR-deficient 15 cells (Fig 2B, left panel) . Rescue of PR in PR-deficient cells (T47D-Y+PR) completely restored PR binding at the low-methylated intronic sequence; however, it only partially restored PR binding at the highly-methylated promoter site, suggesting that hypermethylation at the ESR1 promoter impedes PR binding to this genomic region (Fig 5A) . To test this hypothesis, we treated the PR-rescue cells (T47D-Y +PR) with the demethylating agent 5-azacytidine (5-azaC) or vehicle (control) and then compared the PR binding at the ESR1 locus between control and 5-azaC-treated cells. The results showed that 5-azaC treatment (leading to DNA demethylation) did not affect PR binding at the ESR1 intronic region but it had a tendency to increase PR binding levels at the ESR1 promoter site (Fig 5B) .
The CpG island at the ESR1 promoter contains a canonical progesterone-responsive elements (PRE) encompassing a CpG as well as several half palindromic PRE sites with one or two neighboring CpGs (Fig 6A) . To determine whether the inhibition of PR binding was due directly to the CpG methylation at the PRE or rather to an altered chromatin state, we tested whether PR can bind to methylated or unmethylated forms of PRE oligonucleotides by electrophoresis mobility shift assay (EMSA). We observed that PR bound more efficiently to the unmethylated probes than to their methylated counterparts, especially when the PRE contained two CpGs rather than one (Fig 6, B and C) . Further, an unmethylated PRE, but not a methylated PRE, was a high-affinity competitor in EMSA for an oligonucleotide probe without CpG, which was previously shown to be a strong PR binding site [8] (Fig 6D) .
Moreover, we observed that the CpG-containing PREs were bound by PR less efficiently than the PRE without CpGs (Fig 6, B and C) , suggesting that the presence of CpG, even not methylated, reduces the PR binding affinity.
Finally, we analyzed the methylation of genomic regions bound by PR [20] in the absence of 16 hormones by MeDIP-sequencing method. Despite having a higher CpG content than their flanking genomic regions, all the unliganded PR binding sites had an overall lower level of methylation than their surrounding areas (Fig S4) , suggesting that not only the ESR1 locus but also the other PR binding sites require low levels of methylation for PR binding.
Discussion
The (Fig 7) . Interestingly, the loss of PR specifically affected the ESR1 promoter methylation but not at the ESR1 intronic site that lacks a CpG island, suggesting that PR selectively prevents methylation around CpG islands. In line with our results, demethylation of the ESR1 promoter reactivates ESR1 expression in ER-negative breast cancer cells [4] .
ER+/PR+ breast cancers are much more likely to respond to selective ER modulator (SERM) therapy than breast cancers that lack PR protein (ER+/PR−) [13] . Since the SERM treatments target ER, how the absence of PR affects this kind of therapy is not completely understood.
So far, it was proposed that unliganded PR is a simple marker of ER activity [13] . Our finding that PR contributes to maintain the ESR1 expression in the absence of hormones suggests that the ER+/PR+ breast cancers are more likely to respond to SERM therapy because they could maintain the ER levels higher than the ER+/PR− breast cancers. In agreement with this hypothesis, it has been reported that the breast cancer response to endocrine therapy is directly related to ER levels [42] .
In many cases, the transcriptional regulation of steroid target genes requires the action of regulatory sequences located far away from the promoters [43, 44] . A significant fraction of these distal sequences engages in physical interactions with promoters, suggesting that they 18 act as enhancers [43] . In this study, we showed that the PR binding site within the ESR1 intronic sequence in T47D breast cancer cells exhibits the classical epigenetic marks found at active enhancer regions, including the monomethylation of lysine 4 of histone 3 (H3K4me1), low DNA methylation, and a DNase hypersensitive site [8, 39] . This suggests that PR through its binding to the ESR1 promoter and the enhancer-like intronic sequence could facilitate the interaction between these two genomic regions to enhance the ESR1 (H3K27me3) at ERα binding sites [18] . On the other hand, Mohammed et al. (2015) showed that, in the presence of agonist ligands, PR is not just an ERα-induced target gene but also interacts with ERα to direct its chromatin binding in breast cancer cells, resulting in a unique gene expression pattern that is associated with good clinical outcome [45] . Unliganded PR-B induces robust expression of a subset of estradiol-responsive target genes, with a consequent increased cellular sensitivity to estradiol [14] . In contrast, in T47D breast cancer cells, progesterone-liganded PR negatively regulates a subset of progesterone target genes, including ESR1 [38] . Our finding that unliganded PR is required to maintain ESR1 expression and its DNA methylation profile in the absence of hormones reveals a new molecular 19 mechanism of crosstalk between PR and ER and suggests that hormone binding to PR drastically affects its role in the ESR1 gene regulation. In line with our data, Widschwendter et al. (2004) showed that PR-negative breast cancers have higher ESR1 promoter methylation and lower ESR1 gene expression than PR-positive tumors [46] . Moreover, we observed that PR negative breast carcinoma patients tend to be negative for ER and show higher ESR1 methylation than PR-positive breast carcinomas. However, the copy number loss of PGR was previously observed to be a common feature in ERα-positive luminal B breast cancers [45] , suggesting that different crosstalk between PR and ER could exist, depending on breast cancers subtypes.
Conclusions
In this study, we demonstrate that PR binds to the low-methylated ESR1 promoter and maintains both gene expression and the DNA methylation profile of the ESR1 locus in hormone-free breast cancer cells. These data expand our understanding of the complex crosstalk between PR and ER, and suggest that the analysis of DNA methylation of ESR1 promoter in breast cancer cells can help to design the appropriate targeted therapies for different types of breast cancer patients. 
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